Evidence map›Paper›PMID 36541697›Full record

ArticleNeuro-oncology2023

Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.

Karen Alpen, Claire M Vajdic, Robert J MacInnis, Roger L Milne, Eng-Siew Koh, Elizabeth Hovey, Rosemary Harrup, Fiona Bruinsma, Tuong L Nguyen, Shuai Li and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 2 countries.

Karen AlpenCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-8283-2422
Claire M VajdicThe Kirby Institute, UNSW Sydney, Sydney, New South Wales 2052, Australia.
Robert J MacInnisCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Roger L MilneCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Eng-Siew KohSouth Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Liverpool, New South Wales, Australia.ORCID 0000-0002-1664-2513
Elizabeth HoveyNelune Comprehensive Cancer Centre, Prince of Wales Hospital, Randwick, Sydney, New South Wales 2031, Australia.
Rosemary HarrupRoyal Hobart Hospital, Hobart, Tasmania, Australia.
Fiona BruinsmaCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Tuong L NguyenCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Shuai LiCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8696-8594
David JosephDepartment of Medicine and Surgery, The University of Western Australia, Perth, Western Australia, Australia.
Geza BenkeSchool of Public Health and Preventative Medicine, Monash University, Clayton, Victoria, 3004, Australia.
Pierre-Antoine DuguéCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-2736-3023
Melissa C SoutheyCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
Graham G GilesCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Mark RosenthalThe Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Katharine J DrummondDepartment of Neurosurgery, Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia.
Anna K NowakMedical School, University of Western Australia, Crawley, Western Australia 6008, Australia.
John L HopperCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8567-173X
Miroslaw KapuscinskiCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Enes MakalicCentre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-3017-0871
The University of Melbourne · AUThe University of Western Australia · AUUNSW Sydney · AULiverpool Hospital · AUMonash University · AUPeter MacCallum Cancer Centre · AURoyal Children's Hospital · AUThe Royal Melbourne Hospital · AUUniversity of Tasmania · AU

Funding

Australian Commonwealth GovernmentCancer Council Australia 623204Cancer Council New South WalesCancer Council Victoria AF7305National Health and Medical Research CouncilNHMRC Senior Principal Research FellowNHMRC Senior Research FellowPriority-driven Collaborative Cancer Research SchemeVictorian Cancer Agency Early Career Research Fellow
6 · The paper itself

Abstract

backgroundGlioma accounts for approximately 80% of malignant adult brain cancer and its most common subtype, glioblastoma, has one of the lowest 5-year cancer survivals. Fifty risk-associated variants within 34 glioma genetic risk regions have been found by genome-wide association studies (GWAS) with a sex difference reported for 8q24.21 region. We conducted an Australian GWAS by glioma subtype and sex.

methodsWe analyzed genome-wide data from the Australian Genomics and Clinical Outcomes of Glioma (AGOG) consortium for 7 573 692 single nucleotide polymorphisms (SNPs) for 560 glioma cases and 2237 controls of European ancestry. Cases were classified as glioblastoma, non-glioblastoma, astrocytoma or oligodendroglioma. Logistic regression analysis was used to assess the associations of SNPs with glioma risk by subtype and by sex.

resultsWe replicated the previously reported glioma risk associations in the regions of 2q33.3 C2orf80, 2q37.3 D2HGDH, 5p15.33 TERT, 7p11.2 EGFR, 8q24.21 CCDC26, 9p21.3 CDKN2BAS, 11q21 MAML2, 11q23.3 PHLDB1, 15q24.2 ETFA, 16p13.3 RHBDF1, 16p13.3 LMF1, 17p13.1 TP53, 20q13.33 RTEL, and 20q13.33 GMEB2 (P < .05). We also replicated the previously reported sex difference at 8q24.21 CCDC26 (P = .0024) with the association being nominally significant for both sexes (P < .05).

conclusionsOur study supports a stronger female risk association for the region 8q24.21 CCDC26 and highlights the importance of analyzing glioma GWAS by sex. A better understanding of sex differences could provide biological insight into the cause of glioma with implications for prevention, risk prediction and treatment.

Indexed as

Brain NeoplasmsGlioblastomaGliomaAdultAustraliaCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansIntracellular Signaling Peptides and ProteinsMaleNerve Tissue ProteinsPolymorphism, Single NucleotideIntracellular Signaling Peptides and ProteinsNerve Tissue ProteinsPHLDB1 protein, humanCCDC26glioblastomagliomaGWASsex differences

Identifiers

PMID36541697
PMCPMC10326491
OpenAlexW4312064803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.